On August 3, 2022 GSK plc (LSE/NYSE: GSK) reported that its wholly owned subsidiary, GSK Finance (No.3) plc, is offering to repurchase for cash any and all of its outstanding Exchangeable Senior Notes due 2023 (CUSIP No. 36259 RAA0) (Press release, GlaxoSmithKline, AUG 3, 2022, View Source [SID1234617325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the offer, each holder may require the notes’ issuer to repurchase all or part of such holder’s notes at a price equal to 100% of principal amount. Holders may exercise their right to require the repurchase of notes through 5:00 p.m. ET on 16 September, 2022. As of the date of this notice, approximately $280 million aggregate principal amount of the notes is outstanding.

The offer to repurchase is being made on the terms and subject to the conditions set forth in the indenture governing the notes and the notice of offer to repurchase that has been delivered to holders of the notes. This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell the notes or any other securities.